Long-acting parathyroid hormone

US12233115B2 · kind B2 · utility

Assignee

• Extend Biosciences, Inc. · US

Inventors

• Tarik Soliman · Chester Springs, US
• Daniel B. Hall · Easton, US
• Rachel Covitz · Brookline, US
• Garry Musso · Harwich, US
• Caroline Hill · Brookline, US
• Ahmet Vakkasoglu · Stoneham, US
• Poul Strange · Princeton Junction, US
• Tilmann M. Brotz · Berkeley, US

Key dates

• Filing date: Sep 14, 2023
• Grant date: Feb 25, 2025
• Expiry date: Sep 14, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.